Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Extramedullary Multiple Myeloma
Primary Plasma Cell Leukemia

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: epirubicin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: bortezomib

First Posted Date: 2023-11-21

Last Posted Date: 2024-01-03

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 54

Registration Number: NCT06140966

Locations: 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Other: Electronic Health Record Review
Biological: Epcoritamab
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-11-02

Last Posted Date: 2024-04-25

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 27

Registration Number: NCT06112847

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2023-10-18

Last Posted Date: 2023-10-18

Lead Sponsor: Starton Therapeutics, Inc

Target Recruit Count: 6

Registration Number: NCT06087653

Locations: 🇺🇸
Gabrail Cancer & Research Center, Canton, Ohio, United States

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Phase 3

Recruiting

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Obinutuzumab
Drug: Glofitamab
Drug: Bendamustine
Drug: Tocilizumab
Drug: Lenalidomide

First Posted Date: 2023-10-16

Last Posted Date: 2024-12-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 182

Registration Number: NCT06084936

Locations: 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺
Epworth Hospital, Richmond, Victoria, Australia

and more 59 locations

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Phase 3

Recruiting

Conditions: Relapsed/Refractory Marginal Zone Lymphoma

Interventions: Drug: Orelabrutinib
Drug: Lenalidomide
Drug: Orelabrutinib Placebo
Drug: Rituximab

First Posted Date: 2023-10-13

Last Posted Date: 2024-08-20

Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Target Recruit Count: 324

Registration Number: NCT06082102

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 17 locations

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: idecabtagene vicleucel
Drug: Lenalidomide
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-09-21

Last Posted Date: 2024-08-09

Lead Sponsor: Celgene

Target Recruit Count: 618

Registration Number: NCT06045806

Locations: 🇺🇸
Local Institution - 0147, Columbus, Ohio, United States
🇺🇸
Local Institution - 0102, Boston, Massachusetts, United States
🇩🇪
Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

and more 118 locations

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Chest Radiography
Procedure: Computed Tomography
Biological: Daratumumab
Drug: Dexamethasone
Drug: Lenalidomide
Procedure: Low Dose Computed Tomography of the Whole Body
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Venetoclax
Procedure: X-Ray Imaging
Other: Questionnaire Administration

First Posted Date: 2023-09-18

Last Posted Date: 2024-12-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 100

Registration Number: NCT06042725

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lenalidomide
Biological: Mosunetuzumab
Drug: Polatuzumab Vedotin
Procedure: Positron Emission Tomography

First Posted Date: 2023-08-29

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT06015880

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS

Phase 4

Not yet recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Lenalidomide
Drug: Azacitidine

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 138

Registration Number: NCT06004765

Locations: 🇨🇳
Peking union medical college hospital, Beijing, China

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Phase 1

Recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: CHO-H01
Drug: CHO-H01 at RP2D
Drug: Lenalidomide

First Posted Date: 2023-07-18

Last Posted Date: 2024-07-24

Lead Sponsor: Cho Pharma Inc.

Target Recruit Count: 37

Registration Number: NCT05950165

Locations: 🇨🇳
China Medical University Hospital - Hematology/Oncology - Taichung, Taichung City, Taiwan
🇨🇳
National Cheng Kung University Hospital - Internal Medicine, Tainan, Taiwan
🇨🇳
National Taiwan University Hospital - Hematology And Oncology, Taipei, Taiwan

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy